MENU
XNCR
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION
Xencor (XNCR) Ownership - Who owns Xencor?
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases... Show more
Industry: #Biotechnology
Profile
Industry
Biotechnology
Address
465 North Halstead Street
Phone
+1 626 305-5900
Employees
256
Web
https://www.xencor.com
Details
Group
Domestic Stock Funds
Category
Biotechnology
Capitalization
649.08M
P/E Ratio
N/A
Total Cash
469.57M
Projected Growth
N/A
Total Debt
67.82M
Revenue
127.23M
Risk (Beta)
1.00
Dividend Yield
N/A
Total Cash/Share
6.60
Total Debt/Equity
N/A
Revenue/Share
1.87 USD as % of share price
Fundamentals
XNCR
Capitalization
649M
P/E Ratio
N/A
Risk (Beta)
1.00
Dividend Yield
N/A
Total Cash
470M
Total Cash/Share
6.60
Total Debt
67.8M
Total Debt/Equity
N/A
Projected Growth (PEG Ratio)
N/A
Revenue/Share (as % of the share price)
1.87%
Revenue
127M
ROE
N/A
Book Value
640M
P/B Ratio
1.01
Cash Flow
N/A
Earnings
-3.04
Average Daily Volume YTD
N/A
Common Shares Outstanding - Security Level
712K
Current Ratio
5.89
Current Revenue Per Employee
130928.00
Dividends Per Share - Security
N/A
EBITDA
-161.68M
Float
N/A
Float - Current
N/A
Gross Income Margin
N/A
Revenue To Assets
-23.21
Shares Held By Institutions
2.16B
Shares Outstanding - Current
71.2M
Total Liabilities
265M
Total Volume MTD
N/A
Value
-1
Gain YTD
-60.400
View a ticker or compare two or three
VS
VS
Show more...
Interact to see
Advertisement
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information
General Information
a developer of therapeutics to treat autoimmune and allergic diseases, cancer and other conditions
Industry Biotechnology
Profile
Fundamentals
Details
Industry
Biotechnology
Address
465 North Halstead Street
Phone
+1 626 305-5900
Employees
256
Web
https://www.xencor.com